Damora

Damora is a biotechnology company focused on developing next-generation oral enzyme therapies for the treatment of metabolic and kidney diseases. The company was founded by the former leadership team of Allena Pharmaceuticals, leveraging their deep expertise in oxalate-degrading enzymes to address unmet needs in hyperoxaluria. Damora's lead program, DAM-101, is a potent, orally administered oxalate decarboxylase designed to degrade oxalate within the gastrointestinal tract, thereby reducing its systemic absorption and preventing the formation of kidney stones. By focusing on non-systemic biologics, the company aims to provide safe and effective treatments that protect kidney function without the risks associated with systemic drug exposure. Damora is currently advancing its pipeline toward clinical evaluation to support patients with enteric and primary hyperoxaluria.